| Title : 4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis - Polman_1994_Arch.Neurol_51_1136 |
| Author(s) : Polman CH , Bertelsmann FW , de Waal R , van Diemen HA , Uitdehaag BM , van Loenen AC , Koetsier JC |
| Ref : Archives of Neurology , 51 :1136 , 1994 |
| Abstract : OBJECTIVE: To compare the efficacy and toxicity of 4-aminopyridine and 3,4-diaminopyridine in patients with multiple sclerosis. DESIGN: Intervention study with a before-after design and a randomized, double-blind, crossover design. SETTING: University referral center. PATIENTS: Twenty-four patients with definite multiple sclerosis who had been treated in a previous clinical trial with 4-aminopyridine. INTERVENTIONS: Nonresponders to treatment with 4-aminopyridine (14 patients) were treated with 3,4-diaminopyridine in a 4-week, open-label trial with doses up to 1.0 mg/kg of body weight (before-after design). Responders to treatment with 4-aminopyridine (10 patients) participated in a comparative study of 6 weeks' duration with 4-aminopyridine and 3,4-diaminopyridine according to a randomized, double-blind, double-crossover design. MAIN OUTCOME MEASURES: Neurophysiologic variables for nonresponders, neurologic functions and symptoms on a visual analogue scale for responders, and side effects for both groups. RESULTS: Toxicity profiles of 4-aminopyridine and 3,4-diaminopyridine were different, and systemic tolerability was reduced for 3,4-diaminopyridine. 4-Aminopyridine was more effective than 3,4-diaminopyridine, especially for ambulation, fatigue, and overall daily functioning. CONCLUSION: Our data suggest that, concerning both efficacy and side effects, 4-aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. |
| ESTHER : Polman_1994_Arch.Neurol_51_1136 |
| PubMedSearch : Polman_1994_Arch.Neurol_51_1136 |
| PubMedID: 7980110 |
Polman CH, Bertelsmann FW, de Waal R, van Diemen HA, Uitdehaag BM, van Loenen AC, Koetsier JC (1994)
4-Aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis
Archives of Neurology
51 :1136
Polman CH, Bertelsmann FW, de Waal R, van Diemen HA, Uitdehaag BM, van Loenen AC, Koetsier JC (1994)
Archives of Neurology
51 :1136